Qualigen Therapeutics (NASDAQ:AIXC – Get Free Report) and AEON Biopharma (NASDAQ:AEON – Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Qualigen Therapeutics and AEON Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qualigen Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| AEON Biopharma | 0 | 1 | 1 | 1 | 3.00 |
Profitability
This table compares Qualigen Therapeutics and AEON Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qualigen Therapeutics | N/A | N/A | -83.21% |
| AEON Biopharma | N/A | N/A | -994.63% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Qualigen Therapeutics | N/A | N/A | -$16.97 million | ($7.50) | -0.19 |
| AEON Biopharma | N/A | N/A | -$36.63 million | ($2.43) | -0.38 |
AEON Biopharma is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Qualigen Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
Insider & Institutional Ownership
3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 0.9% of AEON Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
AEON Biopharma beats Qualigen Therapeutics on 7 of the 10 factors compared between the two stocks.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
About AEON Biopharma
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
